1.17
02.20 (01.88%)
As of Nov 25, 2022
AMARIN CORP PLC UK [AMRN]
As of Feb 29, 2024 | Source: Annual Report to the SEC
Company Overview
Amarin Corp Plcuk is a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Our commercialized product, VASCEPA was first approved by the United States, or U.S., Food and Drug Administration, or U.S. FDA, for use as an adjunct to diet to reduce triglyceride, or TG, levels in adult patients with severe hypertriglyceridemia, or the MARINE indication, and commercially launched in 2013.
| Country | United States |
| Phone Number | 353 1 6699 020 |
| Industry | Chemicals And Allied Products |
| Employees | 275 |
| CEO | Patrick Holt |
| Website | www.amarincorp.com |
Key fundamental financials loss of $17.56 million Revenue of $80.17 million Current Reporting Revenue Net Income Profit/Loss Jun 2023 $80.17 million $17.56 million loss Mar 2023 $85.98 million $16.46 ...
Key fundamental financials loss of $17.56 million Revenue of $80.17 million Current Reporting Revenue Net Income Profit/Loss Jun 2023 $80.17 million $17.56 million loss Mar 2023 $85.98 million $16.46 ...
Key fundamental financials loss of $17.56 million Revenue of $80.17 million Current Reporting Revenue Net Income Profit/Loss Jun 2023 $80.17 million $17.56 million loss Mar 2023 $85.98 million $16.46 ...
Key fundamental financials loss of $17.56 million Revenue of $80.17 million Current Reporting Revenue Net Income Profit/Loss Jun 2023 $80.17 million $17.56 million loss Mar 2023 $85.98 million $16.46 ...
Key fundamental financials loss of $17.56 million Revenue of $80.17 million Current Reporting Revenue Net Income Profit/Loss Jun 2023 $80.17 million $17.56 million loss Mar 2023 $85.98 million $16.46 ...
Financial Overview
| Revenue | 306,911 K |
| Profits | -59,112 K |
| Net Cash | -18,412 K |
Management Effectiveness
| Return on Equity | -10.71% |
| Return on Assets | -7.11% |
| Turnover Ratio | 0.36 K |
Profit Ratios
| Gross Margin | 165,541 K |
| Profit as % of Revenues | -280.05% |
| Profit as % of Assets | -6.88% |
| Profit as % of Stockholder Equity | -10.71% |
Balance Sheet and Cash Flow Measures
| Total Assets | 831,684 K |
| Total Liabilities | 279,587 K |
| Operating Cash Flow | 6,880 K |
| Investing Cash Flow | -25,522 K |
| Financing Cash Flow | 230 K |